HS Design will be participating in Landmark’s annual Health Innovations Forum, Thursday March 2nd at Club 101, NYC. This special industry forum will highlight advances in medical device, diagnostics and patient-centric delivery systems. Because of the unique opportunities these innovative technologies present to the market, this forum will be of particular interest to angel and family investors.
This investor, invitation only, event will include presentations from novel start up companies seeking funding. Additional, there will be panel discussions involving personalized medicine and device design innovations. Alfred Slanetz, PhD, CEO of Geneius and former CEO of Bluebird Bio will proved the keynote: “Healthcare innovation, the Changing Landscape of Personalized Medicine”.
Tor Alden, MS., IDSA Principal – HS Design
Tor Alden, Principal of HS Design, will join a panel with William Podd of Landmark Angels, Dan Sterling of Sterling Medical Devices and Scott Nixon of Atrion Medical Products discussing Innovations in Medical Devices. This panel will touch on disrupting innovations that are changing the landscape of our current healthcare system. Additionally, the panel will address the pain points of the disruption and how better to adopt.
About Landmark
Landmark Angels, Based in Greenwich, CT, was formed in 2008 with a core group of 25 people, now numbering approximately 300. Landmark includes accredited venture capital and private equity investors, high net worth investors, former executives of major corporations, successful entrepreneurs, prominent family offices, asset management and hedge funds.
About HS Design
HSD, Based in Gladstone, NJ, is an ISO 13485 certified product development firm with over 40 years of experience. HSD partners in with companies to combine technology, end user’s needs and manufacturing to delivers innovative results in complex medical and life science systems. HSD’s team is comprised of Strategic, User Research, Human Factor, Design, Engineering and Manufacturing experts with a focus of commercialization.